ALLR News and Press, Allarity Therapeutics Inc. From 04/12/24

A look at the top 10 most actives in the United States Beneficient (BENF) rose 44.7% to $0.1 on volume of 79,601,246 shares PaxMedica Inc. (PXMD) rose 123.0% to $0.9183 on volume of 54,446,384 shares NextPlat Corp (NXPL) rose 40.0% to $2.1 on volume of 30,284,097 shares Direxion Daily S...

2024-04-12 09:01:35 ET More on premarket gainers & stock Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript Globe Life Inc. (GL) Q4 2023 Earnings Call Transcript Alterity Therapeutics receives A$3.9M research & development tax incentive refund ...

A look at the top 10 most actives in the United States Nikola Corporation (NKLA) fell 26.7% to $0.717 on volume of 293,193,103 shares PROSHARES TRUST (SQQQ) fell 4.6% to $10.4 on volume of 158,399,098 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.4% to $3.21 on volume o...

A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 96.2% to $0.0785 on volume of 428,216,483 shares Mobile Global Esports Inc. (MGAM) rose 77.8% to $0.216 on volume of 139,335,972 shares PROSHARES TRUST (SQQQ) fell 1.2% to $10.61 on volume of 128,866...

A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 28.8% to $0.0515 on volume of 62,068,605 shares Laser Photonics Corporation (LASE) rose 172.7% to $3.9 on volume of 54,588,758 shares WiSA Technologies Inc. (WISA) fell 6.1% to $0.0217 on volume of 2...

2024-04-08 09:02:03 ET Allarity Therapeutics, Inc. Common Stock (ALLR) announced stock split at a ratio of 1-for-20 on 2024-04-09 ... Full story available on KlickAnalytics.com

2024-04-04 09:28:02 ET More on Allarity Therapeutics Seeking Alpha’s Quant Rating on Allarity Therapeutics Read the full article on Seeking Alpha For further details see: Allarity Therapeutics to implement 1-for-20 reverse stock split

Boston (April 4, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of it...

The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of IXEMPRA ® and dovitinib is de-prioritized The Company has been ab...

Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company has been granted a formal exten...